Invasive Fungal Infection Complicating Treatment With Ibrutinib

Ibrutinib is a selective Bruton’s tyrosine kinase inhibitor (BTKi) approved for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell malignancies. Invasive fungal infections (IFIs) have recently been reported in patients on BTKis despite the absence of significant immunocompromise ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajapakse, Pramuditha, Gupta, Manish, Hall, Rewaida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Infectious Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319755/
https://www.ncbi.nlm.nih.gov/pubmed/34336499
http://dx.doi.org/10.7759/cureus.16009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319755/
https://www.ncbi.nlm.nih.gov/pubmed/34336499
http://dx.doi.org/10.7759/cureus.16009

Ejemplares similares